CNBX Pharmaceuticals Inc. (CNBX)

OTCMKTS: CNBX · Delayed Price · USD
0.0092
0.00 (0.00%)
May 22, 2024, 11:47 AM EDT - Market closed
Market Cap 286.23K
Revenue (ttm) 540,239
Net Income (ttm) -1.25M
Shares Out 31.11M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 54,423
Open 0.0104
Previous Close 0.0092
Day's Range n/a
52-Week Range 0.0092 - 0.0500
Beta 0.87
Analysts n/a
Price Target n/a
Earnings Date n/a

About CNBX

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast canc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol CNBX
Full Company Profile

Financial Performance

In 2023, CNBX's revenue was $410,165, an increase of 1269.13% compared to the previous year's $29,958. Losses were -$3.71 million, -1.56% less than in 2022.

Financial Statements

News

CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma

REHOVOT, Israel and BETHESDA, MD, Nov. 8, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related medicine, announced today that it has acqui...

1 year ago - PRNewsWire

CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy

REHOVOT, Israel and BETHESDA, MD., Oct. 18, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced tod...

1 year ago - PRNewsWire

CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel

REHOVOT, Israel and BETHESDA, Md. , Oct. 13, 2022 /PRNewswire/ - CNBX Pharmaceuticals Inc. (OTC-QB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced to...

1 year ago - PRNewsWire

CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate

REHOVOT, Israel and BETHESDA, Md. , Sept. 29, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

1 year ago - PRNewsWire

CNBX Pharmaceuticals Announces New Patent Granted in Australia

REHOVOT, Israel and BETHESDA, MD., Sept. 28, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced to...

1 year ago - PRNewsWire

CNBX Pharmaceuticals Granted Patent in Hong Kong

TEL AVIV, Israel and BETHESDA, Md. , May 5, 2022  /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, today announ...

2 years ago - PRNewsWire

Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals

TEL AVIV, Israel and BETHESDA, Md. , March 28, 2022 /PRNewswire/ --  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, anno...

2 years ago - PRNewsWire

CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials

TEL AVIV, Israel and BETHESDA, Md., Nov. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announce...

2 years ago - PRNewsWire

Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago

TEL AVIV, Israel and BETHESDA, Md., Oct. 26, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

2 years ago - PRNewsWire

Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors

TEL AVIV, Israel and BETHESDA, Md., Oct. 25, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

2 years ago - PRNewsWire

EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX

TEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

2 years ago - PRNewsWire

CNBX Director, Dr. Inbar Maymon-Pomeranchik, to Participate at MJBizCon in Las Vegas

TEL AVIV, Israel and BETHESDA, Md., Oct. 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

2 years ago - PRNewsWire

CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021

TEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

2 years ago - PRNewsWire

Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer

Cannabics Pharmaceuticals Inc. (OTC:CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent application...

2 years ago - Benzinga

Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer

TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

2 years ago - PRNewsWire

Cannabics Announces New Corporate Logo, New Website and New Company Presentation

TEL AVIV, Israel and BETHESDA, Md., Sept. 30, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a p...

2 years ago - PRNewsWire

Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston

TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announ...

2 years ago - PRNewsWire

Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases

TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announce...

2 years ago - PRNewsWire

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

TEL AVIV, Israel and BETHESDA, Md., Sept. 13, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a p...

2 years ago - PRNewsWire

Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors

TEL AVIV, Israel and BETHESDA, Md., Aug. 23, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announc...

2 years ago - PRNewsWire

World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, Aug. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, ann...

3 years ago - PRNewsWire

Cannabics Pharmaceuticals Appoints a Second Independent Board Member

TEL AVIV, Israel and BETHESDA, Maryland, July 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, an...

3 years ago - PRNewsWire

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

TEL AVIV, Israel and BETHESDA, Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announce...

3 years ago - PRNewsWire

Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice

TEL AVIV, Israel and BETHESDA, Md., June 28, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, release...

3 years ago - PRNewsWire

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

TEL AVIV, Israel and BETHESDA, Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, an...

3 years ago - PRNewsWire